Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.

Human pathology - 1 Jun 2020

He Mai, Abro Brooj, Kaushal Madhurima, Chen Ling, Chen Tiffany, Gondim Mercia, Yan Weisi, Neidich Julie, Dehner Louis P, Pfeifer John D

Abstract excerpt

Synovial sarcoma (SS) is a soft-tissue malignancy that most often affects patients aged between 15 and 40 years, and the prognosis for patients with metastatic disease is generally poor. This study was performed to evaluate checkpoint blockade immunotherapy markers in SS, including tumor mutational burden (TMB), DNA mismatch repair (MMR) status, and PDL-1 (programmed cell death ligand 1), PD1 (programmed cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to CD8 Antigens

Share to DNA Mismatch Repair

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Share to Soft Tissue Neoplasms

Source

Identifiers

PMID: 32387103
DOI: 10.1016/j.humpath.2020.04.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.PMID 32387103Read ↗

Synovial Sarcoma With BRAF V600E Mutation: A Case Report and Literature Review.Semantic proximity Read ↗

Integrative multi-omics analysis reveals molecular subtypes and tumor evolution of synovial sarcomaSemantic proximity Read ↗

BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma.Semantic proximity Read ↗

Precision Oncology in Sarcomas: Divide and ConquerSemantic proximity Read ↗

Molecular Profiling Defines Three Subtypes of Synovial SarcomaSemantic proximity Read ↗

Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in TherapySemantic proximity Read ↗

New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular SubtypeSemantic proximity Read ↗

Intriguing Tumor, Synovial Sarcoma: Hard to Diagnose, Harder to TreatSemantic proximity Read ↗

Sarcoma-The standard-bearer in cancer discovery.Semantic proximity Read ↗

The Biology of Synovial Sarcoma: State-of-the-Art and Future PerspectivesSemantic proximity Read ↗

Opposing immune and genetic forces shape oncogenic programs in synovial sarcomaSemantic proximity Read ↗

Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.